Leishmaniasis
A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
Subtype terms (2)
More specific conditions that are subtypes of Leishmaniasis in the MeSH hierarchy.
- Leishmaniasis, Cutaneous
40 drugs (22 approved, 18 experimental)
- Leishmaniasis, Visceral
24 drugs (12 approved, 12 experimental)
Drugs by status
Approved for this indication (2)
Phase 3 trials (2)
Phase 2 trials (8)
Phase 1 trials (5)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (24)
- Banaras Hindu University
- Centro Internacional de Entrenamiento e Investigaciones Médicas
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Federal University of Minas Gerais
- Ohio State University
- University of Brasilia
- Sarder Patel Medical College
- University of Amsterdam
- International Center for Diarrheal Disease Research
- Drugs for Neglected Diseases Initiative
- Federal University of Sergipe
- SP Medical College, Bikaner
- Federal University of Piaui
- Hospital Infantil Joao Paulo II - FHEMIG
- Federal University of Tocantins
- Rajendra Memorial Research Institute of Medical Sciences
- Kala-azar Medical Research Centre
- Shrimati Hazari Maternity and Medical Care
- Dr. A.K. Aditya Clinic
- University of Nagasaki
- Government of Brazil
- State University of Montes Claros
- PATH
- Medecins Sans Frontieres
Organization Involved with Phase 3 Indications (53)
- Bharat Serums and Vaccines Limited
- Institut Pasteur
- Fundacion Nacional de Dermatologia
- Waisenmedizin e. V. Promoting Access to Essential Medicine
- Fundación Cardiovascular de Colombia
- United States Army
- World Health Organization
- Paulo Roberto Lima Machado
- Addis Ababa University
- University of London
- Federal University of Bahia
- Federal University of Mato Grosso do Sul
- Institute of Tropical Medicine, Belgium
- Kenya Medical Research Institute
- Kerman University of Medical Sciences
- Makerere University
- Mashhad University of Medical Sciences
- Rio de Janeiro State University
- Slotervaart Hospital
- Universidad de Antioquia
- Universidad de Santander
- Universidad Industrial de Santander
- Cayetano Heredia University
- University of Khartoum
- University of Tehran
- University of Freiburg
- Institute of Endemic Diseases, Sudan
- Netherlands Cancer Institute
- Isfahan University
- University of Gondar
- +23 more
Organization Involved with Phase 2 Indications (29)
- Paladin Labs
- Gilead Sciences
- Knight Therapeutics
- AEterna Zentaris
- GlaxoSmithKline
- Immune Design
- Infan Industria Quimica Farmaceutica Nacional
- Centro de Investigaciones Bioclínicas de la Fundación Fader
- Foundation Fader
- Infectious Disease Research Institute
- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Uniformed Services University of the Health Sciences
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Harvard University
- University of Heidelberg
- University of York
- Fast Track Drugs and Biologics LLC
- Universidad Mayor San Simón, Cochabamba, Bolivia.
- Cenetrop
- AB Foundation for Medical Research
- Wellcome Trust
- University of Paris
- Ben Gurion University
- Bill and Melinda Gates Foundation
- German Federal Ministry of Education and Research
- Proyecto OSCAR
- Government of Spain
- Pontifical Catholic University of Rio Grande do Sul
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (4)